SBIR/STTR Research Award

Developing Intravesical Liposomes for Interstitial Cystitis

Award identifier 45a0162f2f8c3fb23e6e94945c1d78d5778b7da95d0b5eaf86ffc1adf07b3685Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$741,288

Program and phase

STTR · Phase II

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Lipella Pharmaceuticals Inc.
Proposal award date
2014-08-01
Contract end date
2016-07-31
UEI
JBVNWFNEEV59
Solicitation number
PA13-235
Topic code
NIDDK

Research abstract

DESCRIPTION provided by applicant Lipella Pharmaceuticals Inc Pittsburgh PA is a clinical stage pharmaceutical company specializing in intravesical therapies for urinary bladder dysfunctions Lipella is submitting a research proposal to the Small Business Technology Transfer program titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot The project proposes to evaluate the safety and efficacy of an experimental drug named LP for the indication of interstitial cystitis bladder pain syndrome IC BPS in a new clinical study The proposal is divided into two specific aims that support the execution of a Lipella sponsored Phase IIB randomized clinical trial to evaluate two different doses of LP in IC BPS patients compared to a placebo dose IC BPS is a poorly understood condition with significant unmet medical needs LP is a liposome formulation delivered directly to the bladder via urinary catheter Liposomes are vesicles composed of phospholipid bilayers separated by aqueous compartments The intended primary effect of LP is to alleviate irritation and pain caused by IC BPS in patients Successful completion of this STTR would provide significant clinical data on a novel therapy for a debilitating syndrome and greatly improve the prospect of bringing the product to market PUBLIC HEALTH RELEVANCE This research proposal is for the National Institutes of Health Small Business Technology Transfer STTR program The project is titled andquot Developing Intravesical Liposomes for Interstitial Cystitisandquot and will further the clinical development of a drg to treat interstitial cystitis bladder pain syndrome IC BPS Up to one million people in the United States of America suffer from IC BPS an incurable chronic disease of the bladder believed to be caused by defects in the epithelial cells lining the bladder lumen There is limited medical therapy for IC BPS The development of safe and effective new treatment for IC BPS is a major unmet need for many Americans

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

14 SBIR/STTR records share this UEI (2006–2022). Reported award amounts total $9,701,253. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.